Arcturus Therapeutics Holdings vs Monte Rosa Therapeutics
Monte Rosa Therapeutics is the larger business, with $124m of revenue in fiscal 2025 against $82.0m for Arcturus Therapeutics Holdings (1.5 times as much). Monte Rosa Therapeutics grew faster (63.5% against -46.1%). Monte Rosa Therapeutics kept more of each dollar of sales as profit: a net margin of -31.2% against -80.2%.
| Latest fiscal year | Arcturus Therapeutics HoldingsARCT, 2025 | Monte Rosa TherapeuticsGLUE, 2025 |
|---|---|---|
| Revenue | $82.0m | $124m |
| Revenue growth | -46.1% | 63.5% |
| Net income | −$65.8m | −$38.6m |
| Operating margin | -93.0% | -43.8% |
| Net margin | -80.2% | -31.2% |
| Return on equity | -28.9% | -16.9% |
| Free cash flow | −$74.5m | −$27.5m |
| Cash | $231m | $130m |
| Total debt | — | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | 0.0% |
| Share buybacks | — | — |
| Employees | 111 | 150 |
| Market value | $268m | $894m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 37 sales |